Navigation Links
Angina drug potentially useful against heart rhythm disorders
Date:3/31/2008

A recently approved angina drug may also represent a powerful new treatment for a rare hereditary syndrome that places teens at risk for sudden cardiac death, according to research presented to today at the 57th Annual Scientific Sessions of the American College of Cardiology (ACC) in Chicago.

Cardiac arrhythmias are electrical malfunctions that throw the heart out of rhythm, causing many of the 330,000 sudden cardiac deaths each year in the United States. Most fatal arrhythmias occur in aging patients when scar tissue left by a heart attack interferes with the heart's electrical system. As many as 1,000 deaths each year, however, are caused by Long QT Syndrome (LQTS), which occurs mostly in teens with otherwise healthy hearts. While rare, LQTS is yielding insights into the much more common post-heart attack arrhythmias, researchers said.

The QT interval is part of the hearts electrical signature as recorded by an electrocardiogram (ECG). The QT represents the time it takes for the hearts lower chambers to reset electrically after each heartbeat. QTc is QT corrected for heart rate, a more accurate measure. In LQTS patients, QTc reset time is prolonged, which makes the heart more susceptible to fatal arrhythmias. The condition may go unnoticed until sports, strong emotions or even loud noises knock the heart out of rhythm, causing loss of pulse and consciousness (syncope). Sudden death will then occur if the heart is not restarted with a defibrillator. Given the current state of awareness, some families have lost a second child before realizing all the children have the syndrome.

In the current, pilot study, researchers found that a drug, ranolazine (brand name Ranexa, CV Therapeutics) shortens the QT interval by about 5 percent; just enough to reduce symptoms and risks associated with one form of LQTS (LQT3-deltaKPQ). It is one of three forms of the disease that together make up 90 percent of LQTS cases. Past studies have shown that
'/>"/>

Contact: Greg Williams
Greg_Williams@urmc.rochester.edu
University of Rochester Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Trial to Test Gene Therapy for Angina in Women
2. Docs Debate Drugs vs. Surgery for Angina
3. Doctors Debate Drugs vs. Surgery for Angina
4. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
5. Common abdominal pain may be due to a potentially treatable newly recognized inflammatory reaction
6. Cone-Beam CT faster, potentially more accurate than conventional mammography
7. Hot liquids release potentially harmful chemicals in polycarbonate plastic bottles
8. Heating Plastic Bottles Releases Potentially Harmful Chemical
9. ASAM Calls for Care in the Use of, and the Prescribing of, Potentially Addictive Substances
10. Cerimon to Conduct a Proof of Concept Study for Basiliximab for Noninfectious Uveitis, a Potentially Sight-Threatening Inflammation of the Eye
11. Regenstrief Institute tapped by CDC to combat potentially catastrophic disease outbreaks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Florida Hospital and MOSI officially announced a transformational ... to come and make a difference in the Tampa Bay ... check to provide the support needed to keep the science ... transform the IMAX Dome Theatre from film to a state-of-the-art ... Dome Theatre in the state of Florida, and it is ...
(Date:7/25/2014)... -- The human brain can preserve oxygen to protect ... finds. Although dehydration significantly reduces blood flow ... the brain compensates by increasing the amount of oxygen ... helped us understand a lot more about how the ... study first author Steven Trangmar, a researcher at Brunel ...
(Date:7/25/2014)... 25, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Ibuprofen and Oxcarbazepine Tablets . ... lot of Ibuprofen and one lot of Oxcarbazepine Tablets, by ... mislabeled packaging. Oxcarbazepine is used for the treatment of certain ... The reason for the recall is that Lot #142588, Expiration ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 A new study ... revealed that 39 percent of all children in the survey ... , The survey looked at 2,505 children during the years of ... four years of age. The final result was that about ... care. Many of these children were from lower-income families and were ...
(Date:7/25/2014)... 25, 2014 A new study of participants ... which are published today in Cancer , found evidence ... 74 who had an abnormal finding on a lung cancer ... of life than did those who were screened and found ... surprise to the researchers. “We expected that participants with an ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5
... http://www.cryocath.com , Toronto Stock Exchange Symbol: CYT, ... leader in cryotherapy products to treat cardiac,arrhythmias, today announced ... Selected Third Quarter Financial and Operational Highlights: ... $9.2 million or a 12.0% increase over ...
... NANJING, China, Aug. 5 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical,Group (NYSE: ... branded generic,pharmaceuticals and manufacturer of the patented anti-cancer biotech,product ... the,quarter ended June 30, 2008., Highlights ... for the second quarter, representing ...
... Mass., Aug. 5 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ... third quarter ended June 30, 2008. The,Company will host ... am,eastern time (details follow below)., The Company reported ... $19.0 million or $0.25 per share for the quarter ...
... IRVINE, Calif., Aug. 5 SectorWatch.biz announces the,availability ... release of,articles and message boards relative to the ... aforementioned equities and the,opportunity for investors to respond ... can view MarketStats by visiting: http://www.SectorWatch.biz ,-a ...
... Goodison goes for gold and aims to give back to Mercy Ships ... ... European Laser Champion and one of Britain,s greatest medal hopes at the ... seagoing charity Mercy Ships which provides free medical care to the people ...
... age management practice, announced the opening of Cenegenics Indiana. ... leader is launching over 2008-2009. The new Cenegenics Indiana ... The center,s established protocols and personalized programs for healthy ... Minutes, 20/20, Nightline and GQ. , ...
Cached Medicine News:Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 2Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 3Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 4Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 5Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 6Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 7Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 8Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 9Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 10Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 11Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 12Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 13Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 12Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 2Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 3Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 4Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 5Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 6Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 7Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 8Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 9Health News:SectorWatch.biz Issues MarketStats for Healthy and Organic Companies ORGC, DF, WFMI, LWAY, COIN, and TOF 2Health News:Olympic Sailing Hopeful Backs Hospital Ship Charity 2Health News:Olympic Sailing Hopeful Backs Hospital Ship Charity 3Health News:Olympic Sailing Hopeful Backs Hospital Ship Charity 4
(Date:7/24/2014)... 24, 2014   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ... the development and commercialization of innovative therapies for the ... PDUFA date for Zalviso remains July 27, 2014.  ... online stating the Food and Drug Administration (FDA) had ... been no notification to the company from the FDA ...
(Date:7/24/2014)... 24, 2014  Restore Health, a leading personalized ... announced that it is now offering pharmacogenetics testing ... individual based upon their particular genetic makeup. Comprehensive ... interaction between a patient,s genetics and their entire ... to provide this new service to healthcare providers ...
(Date:7/24/2014)... Inc. (NASDAQ: UPI ), a medical device ... products to treat voiding dysfunctions, today reported financial ... 30, 2014.  Global revenue for the ... to $4.1 million, as compared to $3.4 million ... Total revenue for the fiscal first quarter of ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
... 4, 2010 Reportlinker.com announces that ... available in its catalogue: ... - Metastatic gastrointestinal cancers represent a ... lack of approved drugs ...
... 4, 2010 AccuVein LLC, the developer of the ... it had been awarded the maximum grant amount from ... grant program supports projects that show significant potential to ... the long-term growth of health care costs. ...
Cached Medicine Technology:Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 2Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 3Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 4Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 5Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 6Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 7Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 8Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 9Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 10Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 11Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 12Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 13Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 14Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 15Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 16Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 17AccuVein Receives Grant for its Award Winning AV300 Vein Illumination System 2
New! Visually superior, micrometer handle, single foot plate, blade extends to 3.0 mm....
... new approach to practice management, built to address ... healthcare market. OPIE was created by practicing O&P ... in this field, so it thinks the way ... than anything else available. If you believe there ...
... a comprehensive pocket-sized reference to ... on the evaluation and management of diseases ... Updated annually. The complete content is available ... for Pocket PC- and Palm-based PDAs are ...
... The Medical Imaging Consultant, PDA Edition ... fellows who may order diagnostic imaging studies. ... device to extensive information that will help ... based on symptoms, and which studies will ...
Medicine Products: